Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are ...

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Last week, the markets wrapped up a shortened trading week (due to Good Friday) with widespread losses, as investors grappled with trade ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030 ... The company is scheduled to release the financial performance on 1 May. Analysts expect $4.79 per share earnings ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE ... followed a Thursday update from Lilly that sent its stock 14.3% higher.

Due to this performance, analysts also recommend investing in dividend stocks. We created this list ... points (see more details here). Eli Lilly and Company (NYSE:LLY) ranks seventh on our ...